Liver biopsy versus noninvasive testing in chronic hepatitis C: Where do we stand in 2008?

Dienstag JL: The role of liver biopsy in chronic hepatitis C. Hepatology 2002, 36(Suppl 1):S152–S160.

NIH consensus statement on management of hepatitis C: 2002. NIH Consens State Sci Statements 2002, 19:1–46.

Manns MP, McHutchison JG, Gordon SC, et al.: PEG-interferon alfa-2b in combination with ribavirin compared to interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C. Lancet 2001, 358:958–965.

Skripenova S, Trainer TD, Krawitt EL, et al.: Variability of grade and stage in simultaneous paired liver biopsies in patients with hepatitis C. J Clin Pathol 2007, 60:321–324.

Regev A, Berho M, Jeffers LJ, et al.: Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002, 97:2614–2618.

Colloredo G, Guido M, Sonzogni A, et al.: Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003, 39:239–244.

Schiano TD, Azeem S, Bodian CA, et al.: Importance of specimen size in accurate needle liver biopsy evaluation of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2005, 3:930–935.

Guido M, Rugge M: Liver biopsy sampling in chronic viral hepatitis. Semin Liver Dis 2004, 24:89–97.

Bedossa P, Dargere D, Paradis V: Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003, 38:1356–1358.

Perrillo RP: The role of liver biopsy in hepatitis C. Hepatology 1997, 26(Suppl 1):57S–61S.

Poynard T, Ratziu V, Benmanov Y, et al.: Fibrosis in patients with chronic hepatitis C: detection and significance. Semin Liver Dis 2000, 20:47–55.

Cadranel JF, Rufat P, Degos F: Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000, 32:477–481.

Matsuzaki K, Murata M, Yoshida K, et al.: Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology 2007, 46:48–57.

Zaman A, Rosen HR, Ingram K, et al.: Assessment of FIBROSpect II to detect hepatic fibrosis in chronic hepatitis C patients. Am J Med 2007, 120:280.e9–280.e14.

Halfon P, Bacq Y, De Muret A, et al.: Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C. J Hepatol 2007, 46:395–402.

Wai CT, Greenson JK, Fontana RJ, et al.: A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003, 38:518–526.

Shaheen AA, Myers RP: Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology 2007, 46:912–921.

Imbert-Bismut F, Ratziu V, Pieroni L, et al.: Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001, 357:1069–1075.

Shaheen AAM, Wan AF, Myers RP: FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastro 2007, 102:2589–2600.

Forns X, Ampurdanes S, Llovet JM, et al.: Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002, 36:986–996.

Patel K, Muir AJ, McHutchison JG. Validation of a simple predictive model for the identification of mild hepatic fibrosis in chronic hepatitis C patients. Hepatology 2003, 37:1222–1223.

Thabut D, Simon M, Myers RP, et al.: Noninvasive prediction of fibrosis in patients with chronic hepatitis C. Hepatology 2003, 37:1220–1221.

Sterling RK, Lissen E, Clumeck N, et al.: Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006, 43:1317–1325.

Vallet-Pichard A, Mallet V, Nalpas B, et al.: FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection—comparison with liver biopsy and fibrotest. Hepatology 2007, 46:32–36.

Kurosaki M, Izumi N: External validation of FIB-4: diagnostic accuracy is limited in elderly populations. Hepatology 2008, 47:352.

Koda M, Matunaga Y, Kawakami M, et al.: FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology 2007, 45:297–306.

Halfon P, Penaranda G, Renou C, et al.: External validation of FibroIndex. Hepatology 2007, 46:280–281.

Patel K, Gordon SC, Jacobson I, et al.: Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004, 41:935–942.

Harrison SA: Is the FIBROSpect II (®) index effective for determining the stage of fibrosis in patients with chronic hepatitis C? Nat Clin Pract Gastroenterol Hepatol 2007:2.

Leroy V, Monier F, Bottari S, et al.: Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol 2004, 99:271–279.

Trocme C, Leroy V, Sturm N, et al.: Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared to MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin. J Viral Hepat 2006, 13:643–651.

Adams LA, Bulsara M, Rossi E, et al.: Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005, 51:1867–1873.

Leroy V, Hilleret MN, Sturm N, et al.: Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol 2007, 46:775–782.

Cales P, Oberti F, Michalak S, et al.: A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005, 42:1373–1381.

Adler M, Gulbis B, Moreno C: The predictive value of FIB-4 versus FibroTest, APRI, FibroIndex, and Forns index to noninvasively estimate fibrosis in hepatitis C and nonhepatitis C liver diseases. Hepatology 2008, 42:762–763.

Sebastiani G, Vario A, Guido M, et al.: Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases. J Viral Hepat 2008, 15:212–218.

Snyder N, Nguyen A, Gajula L, et al.: The APRI may be enhanced by the use of the FIBROSpect II in the estimation of fibrosis in chronic hepatitis C. Clin Chim Acta 2007, 381:119–123.

Sebastiani G, Vario A, Guido M, et al.: Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol 2006, 44:686–693.

Bourliere M, Penaranda G, Renou C, et al.: Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies. J Viral Hepat 2006, 13:659–670.

Baranova A, Younossi ZM: The future is around the corner: noninvasive diagnosis of progressive nonalcoholic steatohepatitis. Hepatology 2008, 47:373–375.

Castera L, Vergniol J, Foucher J, et al.: Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005, 128:343–350.

Huwart L, Peeters F, Sinkus R: Liver fibrosis: non-invasive assessment with MR elastography. NMR Biomed 2006, 19:173–179.

Huwart L, Sempoux C, Salameh N, et al.: Liver fibrosis: noninvasive assessment with MR elastography versus aspartate aminotransferase-to-platelet ratio index. Radiology 2007, 245:458–466.